Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This issue of Px Wire highlights the adherence issues raised by the VOICE trial results and introduces a tool created to help civil society influence PEPFAR annual Country Operational Plans.
Px Wire April-June 2013, Vol. 6, No. 2
Px Wire January-March 2013, Vol. 6, No. 1
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This issue reviews the recent AVAC Advocacy Partners’ Forum, where partners from across sub-Saharan Africa and beyond met and discussed goals for the year ahead. This issue also covers some key content and messages from the PEPFAR Blueprint.
Px Wire October-December 2012, Vol. 5, No. 4
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This issue of Px Wire features an advocates’ guide to the “sieve analysis” from the RV144 vaccine trial. This latest follow-up investigation provided further detail about the partial protection associated with the vaccine strategy. This issue also updates readers with the latest on trials of ARV-containing vaginal rings—the next frontier in microbicide development.
Px Wire July-September 2012, Vol. 5, No. 3
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. As this issue of Px Wire went to press, the US Food and Drug Administration (FDA) announced its approval of daily oral TDF/FTC for PrEP. The issue reviews global PrEP developments and presents an infographic summarizing progress towards beginning to end the AIDS epidemic. In addition, this issue includes a list of prevention research-related sessions at AIDS 2012.
Too Little Too Slow: Results from from civil society monitoring of male circumcision for HIV prevention in Uganda
A jointly-authored report by Ugandan civil society groups taking stock of progress and challenges in Uganda’s voluntary medical male circumcision program as of 2012. Makes recommendations for future action, and highlights examples of best practices in the country.
GPP Blueprint for Stakeholder Engagement
The GPP Blueprint is a companion to the Good Participatory Practice guidelines for biomedical HIV prevention research. It is a step-by-step guide designed for the research team members in charge of stakeholder engagement. It presents questions, worksheets and explanations that can guide and generate a stakeholder engagement plan for a specific trial or research program.
Female-Initiated HIV Prevention: What will we learn from upcoming trials?
A 2007 document developed in anticipation of data from the Carraguard microbicide and MIRA diaphragm trials of women-initiated prevention strategies. It contains explanations of trial design and possible outcomes.
An Action Agenda to End AIDS: Critical actions from 2012-2016 to begin to end the HIV/AIDS pandemic
Released at AIDS 2012, this report lays out a plan for beginning to end HIV/AIDS. It includes clear time-bound outcome targets, as well as the responsibilities of different stakeholders to achieve these targets.
Anticipo de los Resultados de Ensayos de PrEP: Una poderosa herramienta nueva para la prevención del VIH podría estar cerca. ¿Estamos preparados para ella?
A 2008 document providing background information on pre-exposure prophylaxis (PrEP) and discussing efficacy trials that were then planned and ongoing. It discusses the research agenda and key advocacy priorities to move PrEP research forward.
Trials of Intermittent Dosing of Pre-Exposure Prophylaxis (PrEP): Summary from an AVAC think tank
Four-page summary of 2008 meeting on possibilities for intermittent PrEP research.